Nantkwest Inc (NASDAQ:NK) insider Barry J. Simon sold 13,737 shares of the business’s stock in a transaction dated Friday, June 19th. The stock was sold at an average price of $9.00, for a total transaction of $123,633.00. Following the completion of the sale, the insider now owns 3,204,243 shares in the company, valued at $28,838,187. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Shares of NK opened at $12.14 on Friday. The company’s fifty day simple moving average is $6.41 and its 200-day simple moving average is $4.82. The company has a market cap of $1.16 billion, a P/E ratio of -17.85 and a beta of 3.06. The company has a current ratio of 3.10, a quick ratio of 3.10 and a debt-to-equity ratio of 0.10. Nantkwest Inc has a twelve month low of $1.01 and a twelve month high of $13.11.
Nantkwest (NASDAQ:NK) last posted its quarterly earnings data on Monday, May 11th. The biotechnology company reported ($0.19) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.17) by ($0.02). The firm had revenue of $0.02 million during the quarter. Nantkwest had a negative return on equity of 51.94% and a negative net margin of 112,350.85%. Analysts predict that Nantkwest Inc will post -0.54 earnings per share for the current fiscal year.
Several research firms recently commented on NK. Zacks Investment Research lowered Nantkwest from a “buy” rating to a “hold” rating in a research report on Tuesday, March 31st. ValuEngine raised Nantkwest from a “sell” rating to a “hold” rating in a research note on Tuesday, March 3rd. Finally, BidaskClub raised Nantkwest from a “buy” rating to a “strong-buy” rating in a research report on Thursday.
Several institutional investors and hedge funds have recently added to or reduced their stakes in NK. FNY Investment Advisers LLC purchased a new position in Nantkwest in the 1st quarter worth about $28,000. GM Advisory Group Inc. purchased a new stake in Nantkwest in the 1st quarter valued at about $31,000. National Asset Management Inc. bought a new position in Nantkwest in the 4th quarter worth about $46,000. GSA Capital Partners LLP purchased a new position in shares of Nantkwest during the first quarter worth approximately $38,000. Finally, Squarepoint Ops LLC bought a new stake in shares of Nantkwest during the first quarter valued at approximately $39,000. 6.19% of the stock is currently owned by hedge funds and other institutional investors.
Nantkwest Company Profile
NantKwest, Inc, a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and NANT cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells.
Further Reading: Hedge Funds – How They Work For Investors
Receive News & Ratings for Nantkwest Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nantkwest and related companies with MarketBeat.com's FREE daily email newsletter.